Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.944 USD | +2.99% | +2.98% | -33.06% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.06% | 139M | |
+9.93% | 118B | |
+10.10% | 106B | |
-11.45% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.61% | 15.97B | |
+6.49% | 14.03B | |
+16.42% | 11.67B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc., Q4 2023 Earnings Call, Mar 05, 2024